Janney Montgomery Scott LLC Purchases 349 Shares of Amedisys Inc (NASDAQ:AMED)

Janney Montgomery Scott LLC raised its position in Amedisys Inc (NASDAQ:AMED) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,232 shares of the health services provider’s stock after purchasing an additional 349 shares during the period. Janney Montgomery Scott LLC’s holdings in Amedisys were worth $1,209,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Advisory Services Network LLC lifted its holdings in shares of Amedisys by 7.6% during the 2nd quarter. Advisory Services Network LLC now owns 1,098 shares of the health services provider’s stock worth $133,000 after acquiring an additional 78 shares during the last quarter. Oakbrook Investments LLC lifted its holdings in shares of Amedisys by 4.8% during the 3rd quarter. Oakbrook Investments LLC now owns 2,200 shares of the health services provider’s stock worth $288,000 after acquiring an additional 100 shares during the last quarter. Financial Enhancement Group LLC lifted its holdings in shares of Amedisys by 17.8% during the 2nd quarter. Financial Enhancement Group LLC now owns 855 shares of the health services provider’s stock worth $104,000 after acquiring an additional 129 shares during the last quarter. NEXT Financial Group Inc lifted its holdings in shares of Amedisys by 19.8% during the 3rd quarter. NEXT Financial Group Inc now owns 810 shares of the health services provider’s stock worth $106,000 after acquiring an additional 134 shares during the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Amedisys by 25.6% during the 2nd quarter. Captrust Financial Advisors now owns 750 shares of the health services provider’s stock worth $91,000 after acquiring an additional 153 shares during the last quarter. 88.11% of the stock is owned by hedge funds and other institutional investors.

In other Amedisys news, COO Christopher Gerard sold 350 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $134.79, for a total value of $47,176.50. Following the completion of the sale, the chief operating officer now directly owns 25,381 shares of the company’s stock, valued at $3,421,104.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott G. Ginn sold 7,690 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $145.17, for a total transaction of $1,116,357.30. The disclosure for this sale can be found here. Insiders sold 9,740 shares of company stock valued at $1,395,053 over the last three months. 2.90% of the stock is currently owned by insiders.

A number of research firms have recently issued reports on AMED. Royal Bank of Canada lifted their price objective on shares of Amedisys to $150.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Stephens reaffirmed an “equal weight” rating and set a $145.00 price objective on shares of Amedisys in a report on Tuesday, October 22nd. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. UBS Group lifted their price objective on shares of Amedisys from $144.00 to $154.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Barclays lifted their price objective on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 5th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $145.36.

Amedisys stock opened at $149.25 on Friday. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.73 billion, a PE ratio of 41.12, a P/E/G ratio of 2.03 and a beta of 1.38. The firm has a fifty day simple moving average of $133.62 and a two-hundred day simple moving average of $126.38. Amedisys Inc has a twelve month low of $103.76 and a twelve month high of $154.14.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.25. The business had revenue of $494.63 million during the quarter, compared to the consensus estimate of $494.14 million. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The firm’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 earnings per share. As a group, equities analysts expect that Amedisys Inc will post 4.39 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: Why is Cost of Capital Important?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.